Marisa Wexler, MS, senior science writer —

For more than 40% of people with pulmonary fibrosis (PF), obtaining an accurate diagnosis takes a year or longer, according to a European survey. As noted by the international team of researchers who conducted the study, survey findings highlighted “a major need for more information and support during and…

Measuring the levels of certain molecules in the blood could be useful for distinguishing idiopathic pulmonary fibrosis (IPF) from other types of lung disease, according to a recent study. The study, “Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease,”…

Switching antifibrotic treatment is generally well-tolerated among people with idiopathic pulmonary fibrosis (IPF), and those who did generally lived several years longer than those who did not, a study from Japan reports. Findings suggest that switching from one antifibrotic to another “is feasible and may improve prognosis [disease course]…

The Washington Research Foundation (WRF) has awarded a $250,000 grant to support the development of a novel miniprotein binder to help treat idiopathic pulmonary fibrosis (IPF). The grant was awarded to Anindya Roy, PhD, an acting instructor and senior fellow at the University of…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

Vicore Pharma and Alex Therapeutics are collaborating to develop a new phone app that could help improve the mental health of people with idiopathic pulmonary fibrosis (IPF). Vicore will own all rights to the new clinical program, called VP04, in exchange for various payments and royalties to…

Treatment with Ofev (nintedanib) is safe and can preserve lung function in people with idiopathic pulmonary fibrosis (IPF) who are elderly or have several other health conditions, a new study indicates. The study, “Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who…

Axatilimab, an investigational therapy being developed by Syndax Pharmaceuticals, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for idiopathic pulmonary fibrosis (IPF). The FDA gives orphan drug status to medications that have the potential to substantially improve care…

Thanks to a $5 million donation from a grateful patient, Virginia Commonwealth University (VCU) Health is expanding its programs to treat those with lung diseases like pulmonary fibrosis (PF). After his escape from Yugoslavia in the 1950s, Bill Belanich came to the U.S., where he took a job installing…

Amgen will acquire Rodeo Therapeutics, along with its preclinical program focused on the development of potential therapies for inflammatory and fibrotic diseases like pulmonary fibrosis (PF). “With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and…